

## NEURO SPARK™

### CLINICAL APPLICATIONS

- Increases neurotransmitters in the brain
- Source of antioxidants to protect brain cells
- Increases alpha brain waves
- Strengthens synapses

**Centrophenoxine** treatment in a mammalian study significantly increased maximum lifespan by 26.5%. It also significantly improved motor function in a Parkinson's study. **Bisibuthiamine** is an improved version of Vitamin B1, that passes the blood-brain barrier. It signals Acetylcholine which improves memory function. **Trans-Ferulic Acid** works to enhance both memory and learning ability due to its cerebral antioxidant effects.



### DISCUSSION

Regen Labs Neuro Spark™ has a proprietary blend of centrophenoxine, sulbutiamine, and Trans-Ferulic Acid. The combination of these ingredients greatly improves memory and learning. In addition, Neuro Spark contains six more potent ingredients proven to enhance brain function, including Bacopa Extract, L-Tyrosine, Citicoline, Phosphatidylserine 20%, Forskolin Extract, and Huperzine A.

**Bacopa Monnieri Extract** comes from the ancient Bacopa herb, which helps improve memory and reduce anxiety.

**L-Tyrosine** is a form of the amino acid tyrosine, which helps improve memory and thinking skills, cope with sleep deprivation, and boost mental sharpness.

**Citicoline** is a brain chemical that can be taken orally as a supplement. It improves vision, helps deal with memory loss, and can help with other brain conditions.

**Phosphatidylserine** is a naturally occurring lipid that covers and protects cells in the brain to promote healthy cognitive function.

**Forskolin extract** comes from the root of a plant in the mint family. This ingredient can support weight loss and has other potential uses, such as treating asthma and cancer, improving heart health, treating glaucoma, lowering blood pressure, and stimulating suntanning.

**Huperzine A** is a chemical derived from Chinese club moss or fir club moss plants. It is used for the treatment of Alzheimer's disease, memory enhancement, and age-related memory impairment.

All of these ingredients within Neuro Spark™ work together to reduce brain fog, enhance cognitive function, reduce oxidative stress, and increase your body's natural ability to fight memory loss.

### NUTRITION

SUPPLEMENT FACTS		
Serving Size		
2 Capsules   Servings: 30		
	Amount Per Serving	%DV
Neuro Spark™ Cognition Blend	1000mg	*
Trans-Ferulic Acid		
Centrophenoxine		
Bisibuthiamine		
Bacopa Extract		
L-Tyrosine	250mg	*
Citicoline	150mcg	*
Phosphatidylserine 20%	100mg	*
Forskolin Extract	10mg	*
Huperzine A	100mg	*
Other Ingredients		
Hydroxypropyl Methylcellulose, Rice Flour, Silicon Dioxide		
*Daily Value Not Established		

**DIRECTIONS:** Take 2 capsules daily or as needed. Do not exceed more than 2 capsules in a 24h period.

+ These statements have not been evaluated by The Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

## NEURO SPARK™

### REFERENCES

1. Hidese S, Ogawa S, Ota M, et al. *Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial.* *Nutrients.* 2019;11(10):2362. Published 2019 Oct 3. doi:10.3390/nu1102362
2. Aguiar S, Borowski T. *Neuropharmacological review of the nootropic herb Bacopa monnieri.* *Rejuvenation Res.* 2013;16(4):313-326. doi:10.1089/rej.2013.1431
3. Kumar N, Pruthi V. *Potential applications of ferulic acid from natural sources.* *Biotechnol Rep (Amst).* 2014;4:86-93. Published 2014 Sep 16. doi:10.1016/j.btre.2014.09.002
4. Butterworth RF. *Thiamin deficiency and brain disorders.* *Nutr Res Rev.* 2003;16(2):277-284. doi:10.1079/NRR200367
5. Qian ZM, Ke Y. *Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer's Disease?* *Front Aging Neurosci.* 2014;6:216. Published 2014 Aug 19. doi:10.3389/fnagi.2014.00216
6. Marcer D, Hopkins SM. *The differential effects of meclofenoxate on memory loss in the elderly.* *Age Ageing.* 1977;6(2):123-131. doi:10.1093/ageing/6.2.123
7. Glees P, Spoerri PE. *CentrophenoXin-induzierter Abbau und Abtransport von Lipofuszin. Eine elektronenmikroskopische Studie [CentrophenoXin-induced dissolution and removal of lipofuscin. An electron microscopic study (author's transl)].* *Arzneimittelforschung.* 1975;25(10):1543-1548.
8. Marcer D, Hopkins SM. *The differential effects of meclofenoxate on memory loss in the elderly.* *Age Ageing.* 1977;6(2):123-131. doi:10.1093/ageing/6.2.12
9. Oliver JE, Restell M. *Serial testing in assessing the effect of meclofenoxate on patients with memory defects.* *Br J Psychiatry.* 1967;113(495):219-222. doi:10.1192/bjp.113.495.219
10. Ito H, Kudo Y, Kabeshima Y, Nobushima S, Komine K. *Double-blind controlled trial of lucidril (meclofenoxate) in the post-traumatic syndrome, especially dizziness.* *Folia Psychiatr Neurol Jpn.* 1968;22(1):23-42. doi:10.1111/j.1440-1819.1968.tb01307.x
11. Pék G, Fülöp T, Zs-Nagy I. *Gerontopsychological studies using NAI ('Nürnbergger Alters-Inventar') on patients with organic psychosyndrome (DSM III, Category 1) treated with centrophenoXine in a double blind, comparative, randomized clinical trial.* *Arch Gerontol Geriatr.* 1989;9(1):17-30. doi:10.1016/0167-4943(89)90021-6
12. Popa R, Schneider F, Mihalas G, et al. *Antagonic-stress superiority versus meclofenoxate in gerontopsychiatry (alzheimer type dementia).* *Arch Gerontol Geriatr.* 1994;19 Suppl 1:197-206. doi:10.1016/s0167-4943(05)80065-2
13. Dubois B, Zaim M, Touchon J, et al. *Effect of six months of treatment with V0191 in patients with suspected prodromal Alzheimer's disease.* *J Alzheimers Dis.* 2012;29(3):527-535. doi:10.3233/JAD-2012-111370
14. Mosharraf AH, Petkov VD, Petkov VV. *Effects of meclofenoxate and citicholine on learning and memory in aged rats.* *Acta Physiol Pharmacol Bulg.* 1987;13(4):17-24.
15. Petkov VD, Mosharraf AH, Petkov VV. *Comparative studies on the effects of the nootropic drugs adafenoxate, meclofenoxate and piracetam, and of citicholine on scopolamine-impaired memory, exploratory behavior and physical capabilities (experiments on rats and mice).* *Acta Physiol Pharmacol Bulg.* 1988;14(1):3-13.
16. Voronina TA, Garibova TL, Trofimov SS, Sopyev ZhA, Petkov VD, Lazarova MB. *Comparative studies on the influence of ONK (N(5-hydroxynicotinoyl) glutamic acid), piracetam and meclofenoxate on the learning- and memory-impairing effect of scopolamine, clonidine, and methergoline.* *Acta Physiol Pharmacol Bulg.* 1991;17(4):8-16.
17. Nehru B, Bhalla P, Garg A. *Evidence for centrophenoXine as a protective drug in aluminium induced behavioral and biochemical alteration in rat brain.* *Mol Cell Biochem.* 2006;290(1-2):33-42. doi:10.1007/s11010-006-9125-7
18. Liao Y, Wang R, Tang XC. *CentrophenoXine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats.* *Acta Pharmacol Sin.* 2004;25(12):1590-1596.
19. Zs-Nagy I. *On the role of intracellular physicochemistry in quantitative gene expression during aging and the effect of centrophenoXine. A review.* *Arch Gerontol Geriatr.* 1989;9(3):215-229. doi:10.1016/0167-4943(89)90042-3
20. Sharma D, Maurya AK, Singh R. *Age-related decline in multiple unit action potentials of CA3 region of rat hippocampus: correlation with lipid peroxidation and lipofuscin concentration and the effect of centrophenoXine.* *Neurobiol Aging.* 1993;14(4):319-330. doi:10.1016/0197-4580(93)90117-t
21. Hochschild R. *Effect of dimethylaminoethyl p-chlorophenoxyacetate on the life span of male Swiss Webster Albino mice.* *Exp Gerontol.* 1973;8(4):177-183. doi:10.1016/0531-5565(73)90024-7
22. Nehru B, Verma R, Khanna P, Sharma SK. *Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoXine.* *Brain Res.* 2008;1201:122-127. doi:10.1016/j.brainres.2008.01.074
23. Patro N, Sharma SP, Patro IK. *Lipofuscin accumulation in ageing myocardium & its removal by meclofenoxate.* *Indian J Med Res.* 1992;96:192-198.
24. Spoerri PE, Glees P, El Ghazzawi E. *Accumulation of lipofuscin in the myocardium of senile guinea pigs: dissolution and removal of lipofuscin following dimethylaminoethyl p-chlorophenoxyacetate administration. An electron microscopic study.* *Mech Ageing Dev.* 1974;3(5-6):311-321. doi:10.1016/0047-6374(74)90027-x
25. Parson SJ, Russell SD, Bennett MK, et al. *Increased lipofuscin on endomyocardial biopsy predicts greater cardiac improvement in adolescents and young adults.* *Cardiovasc Pathol.* 2012;21(4):317-323. doi:10.1016/j.carpath.2011.11.002
26. Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K. *Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials.* *Prog Neuropsychopharmacol Biol Psychiatry.* 2004;28(7):1099-1107. doi:10.1016/j.pnpbp.2004.05.045
27. Fisher MC, Zeisel SH, Mar MH, Sadler TW. *Perturbations in choline metabolism cause neural tube defects in mouse embryos in vitro.* *FASEB J.* 2002;16(6):619-621. doi:10.1096/fj.01-0564fje
28. Merchenthaler I, Lane M, Sabnis G, et al. *Treatment with an orally bioavailable prodrug of 17 $\beta$ -estradiol alleviates hot flashes without hormonal effects in the periphery.* *Sci Rep.* 2016;6:30721. Published 2016 Aug 1. doi:10.1038/srep30721
29. Riga S, Riga D, Schneider F. *Prolongevity medicine: Antagonic-Stress drug in distress, geriatrics, and related diseases. II. Clinical review--2003.* *Ann N Y Acad Sci.* 2004;1019:401-405. doi:10.1196/annals.1297.072